LC-MS/MS monitoring of the colorectal carcinoma cellular uptake and entrapment of sorafenib and its N-oxide active metabolite
Copyright © 2022 Elsevier B.V. All rights reserved..
Sorafenib (SOR) is a multikinase inhibitor with a mild activity against colorectal cancer cells due to multi-drug resistance mechanisms. Potentiated SOR activity was expected upon combination with some ginger derived compounds due to their interference with intracellular drug metabolism. Studying such combination necessitates the development of a sensitive validated LC-MS/MS method for the determination of intra and extracellular concentration of SOR and its N-oxide metabolite (SNX) in colorectal cancer cells. SOR, SNX and the internal standard (diclofenac sodium) were efficiently separated on Eclipse plus C18 column (3.0 ×150 mm, 5 µm) using isocratic elution with acetonitrile and 0.01 M ammonium formate aqueous solution containing 0.1% formic acid (69:31, v/v). Sample pretreatment using solid phase extraction was optimized and the mean percent recoveries were more than 97.01% for both analytes. Detection was conducted at positive ion multiple reaction monitoring (MRM) mode and the monitored mass transitions were 465.2 → 252.2 for SOR and 481.1 → 286.0 for SNX. The method was linear over the range 0.25 - 200.00 ng/mL (r2 ≥ 0.9992) for SOR and 0.10 - 125.00 ng/mL (r2 ≥ 0.9990) for SNX in both intra and extracellular matrices. The lower limits of quantification (LLOQ) were 0.25 and 0.10 ng/mL for SOR and SNX, respectively. Accuracies were within 94.25 - 109.45% and precision CV values did not exceed 7.63%. The method was able to monitor the cellular uptake and entrapment of both analytes and to prove the positive effect of the ginger derived compounds on SOR activity.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:213 |
---|---|
Enthalten in: |
Journal of pharmaceutical and biomedical analysis - 213(2022) vom: 10. Mai, Seite 114687 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Elawady, Tarek [VerfasserIn] |
---|
Links: |
---|
Themen: |
9ZOQ3TZI87 |
---|
Anmerkungen: |
Date Completed 05.04.2022 Date Revised 05.04.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.jpba.2022.114687 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM33771617X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM33771617X | ||
003 | DE-627 | ||
005 | 20231225235041.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jpba.2022.114687 |2 doi | |
028 | 5 | 2 | |a pubmed24n1125.xml |
035 | |a (DE-627)NLM33771617X | ||
035 | |a (NLM)35240408 | ||
035 | |a (PII)S0731-7085(22)00108-X | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Elawady, Tarek |e verfasserin |4 aut | |
245 | 1 | 0 | |a LC-MS/MS monitoring of the colorectal carcinoma cellular uptake and entrapment of sorafenib and its N-oxide active metabolite |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 05.04.2022 | ||
500 | |a Date Revised 05.04.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2022 Elsevier B.V. All rights reserved. | ||
520 | |a Sorafenib (SOR) is a multikinase inhibitor with a mild activity against colorectal cancer cells due to multi-drug resistance mechanisms. Potentiated SOR activity was expected upon combination with some ginger derived compounds due to their interference with intracellular drug metabolism. Studying such combination necessitates the development of a sensitive validated LC-MS/MS method for the determination of intra and extracellular concentration of SOR and its N-oxide metabolite (SNX) in colorectal cancer cells. SOR, SNX and the internal standard (diclofenac sodium) were efficiently separated on Eclipse plus C18 column (3.0 ×150 mm, 5 µm) using isocratic elution with acetonitrile and 0.01 M ammonium formate aqueous solution containing 0.1% formic acid (69:31, v/v). Sample pretreatment using solid phase extraction was optimized and the mean percent recoveries were more than 97.01% for both analytes. Detection was conducted at positive ion multiple reaction monitoring (MRM) mode and the monitored mass transitions were 465.2 → 252.2 for SOR and 481.1 → 286.0 for SNX. The method was linear over the range 0.25 - 200.00 ng/mL (r2 ≥ 0.9992) for SOR and 0.10 - 125.00 ng/mL (r2 ≥ 0.9990) for SNX in both intra and extracellular matrices. The lower limits of quantification (LLOQ) were 0.25 and 0.10 ng/mL for SOR and SNX, respectively. Accuracies were within 94.25 - 109.45% and precision CV values did not exceed 7.63%. The method was able to monitor the cellular uptake and entrapment of both analytes and to prove the positive effect of the ginger derived compounds on SOR activity | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Cell line | |
650 | 4 | |a LC-MS/MS | |
650 | 4 | |a Solid phase extraction | |
650 | 4 | |a Sorafenib | |
650 | 4 | |a Sorafenib N-oxide | |
650 | 7 | |a Oxides |2 NLM | |
650 | 7 | |a Sorafenib |2 NLM | |
650 | 7 | |a 9ZOQ3TZI87 |2 NLM | |
700 | 1 | |a Al-Abd, Ahmed M |e verfasserin |4 aut | |
700 | 1 | |a Khedr, Alaa |e verfasserin |4 aut | |
700 | 1 | |a El-Enany, Nahed |e verfasserin |4 aut | |
700 | 1 | |a Belal, Fathalla |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of pharmaceutical and biomedical analysis |d 1983 |g 213(2022) vom: 10. Mai, Seite 114687 |w (DE-627)NLM012641928 |x 1873-264X |7 nnns |
773 | 1 | 8 | |g volume:213 |g year:2022 |g day:10 |g month:05 |g pages:114687 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jpba.2022.114687 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 213 |j 2022 |b 10 |c 05 |h 114687 |